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Introduction: Although histology has not consistently been associ-
ated with treatment outcome in advanced non-small cell lung cancer,
a recent phase III trial comparing pemetrexed plus cisplatin and
gemcitabine plus cisplatin (GC) demonstrated better efficacy for
pemetrexed plus cisplatin in nonsquamous (adenocarcinoma and
large cell carcinoma) carcinoma than in squamous cell carcinoma.
Herein, retrospective analysis is used to explore the potential pre-
dictive and prognostic role of non-small cell lung cancer histology in
patients treated with three first-line, platinum-based regimens.
Methods: Survival and time to progression (TTP) data from a phase
III trial comparing paclitaxel plus carboplatin (PCb), GC, and
vinorelbine plus cisplatin (VC) were analyzed. Using Cox multiple
regression, factors for one model included treatment (PCb, GC, and
VC), histology (squamous, adenocarcinoma, large cell, and other),
gender, Eastern Cooperative Oncology Group performance status
(0/1 and 2), stage (IIIB and IV), number of metastatic sites (1 and
1), and smoking history (yes or no). In another model, histology
was simply considered as squamous versus nonsquamous. An inter-
action value of p  0.10 was considered significant.
Results: Baseline patient and disease characteristics for the 607
treated patients were balanced among the arms. No significant
treatment-by-histology interaction was seen in either model for
either end point. Nevertheless, histology was a significant prognostic
factor for survival in the first model (p  0.0183) and marginally
significant for TTP (p  0.0783). Subsequent pairwise comparisons
of histology groups demonstrated a survival advantage for squamous
cell carcinoma over adenocarcinoma (p  0.0021).
Conclusions: Histology was not predictive of PCb, GC, or VC treat-
ment effect for either survival or TTP. Histology was prognostic for
survival, with better outcomes associated with squamous cell carci-
noma.
Key Words: Predictive factor, Prognostic factor, Histology, Non-
small cell lung cancer.
(J Thorac Oncol. 2009;4: 1568–1571)
Tumor histology has not consistently been identified as aprognostic factor in patients with advanced non-small cell
lung cancer (NSCLC).1–3 Nevertheless, a preplanned subset
analysis by histology in a recent, large, phase III study
showed longer survival for pemetrexed plus cisplatin than
gemcitabine plus cisplatin (GC) in patients with nonsqua-
mous NSCLC histology, whereas patients with squamous cell
carcinoma had shorter survival with pemetrexed/cisplatin
compared with GC.4 Similarly, phase II and III studies
showed that patients with nonsquamous NSCLC experience
better efficacy with pemetrexed-containing regimens.5–8
These findings indicate that histology is a predictive factor for
efficacy outcomes of pemetrexed-containing regimens in pa-
tients with advanced NSCLC.
Because histology has been associated with efficacy for
pemetrexed-containing regimens, the question remains
whether histology is predictive of outcomes for other cyto-
toxic regimens. This retrospective analysis explored the po-
tential predictive and prognostic role of histology in a phase
III study comparing three first-line, platinum-based regimens
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for advanced NSCLC: GC, paclitaxel plus carboplatin (PCb),
and vinorelbine plus cisplatin (VC).9
METHODS
Patients
This retrospective analysis was conducted using the
patient database of a previously published study9 in which
patients were considered eligible according to the following
criteria: chemonaive, histologically or cytologically con-
firmed stage IIIB (wet or dry) or stage IV NSCLC, 1
measurable lesion (World Health Organization criteria), an
Eastern Cooperative Oncology Group performance status
(PS) of 0 to 2, and adequate organ function. Study design and
treatment schema were previously published. Patients re-
ceived up to six cycles of gemcitabine 1250 mg/m2 on days
1 and 8 plus cisplatin 75 mg/m2 on day 2 of a 21-day cycle
(GC); paclitaxel 225 mg/m2 plus carboplatin AUC 6 mg/ml/
min, both on day 1 every 21 days (PCb); or vinorelbine 25
mg/m2 on days 1, 8, 15, and 22 plus cisplatin 100 mg/m2 on
day 1 every 28 days (VC).
Statistical Methods
This retrospective analysis incorporated all randomized
patients who received treatment. Cox-adjusted analyses of over-
all survival (OS) (measured from randomization to death) and
time to progression (TTP) (measured from randomization to
disease progression or death) were used to determine the effects
of the following factors: treatment (PCb, GC, and VC), gender,
Eastern Cooperative Oncology Group PS (0/1 and 2), disease
stage (IIIB and IV), number of metastatic sites (1 and 1),
smoking history (yes or no), and histology (model 1: squamous
carcinoma, adenocarcinoma, large cell carcinoma, or other;
model 2: squamous or nonsquamous). Median survival was
estimated using the Kaplan-Meier method.10 Predictive associ-
ations were concluded if there was a significant (p  0.10)
treatment-by-characteristic interaction within the regression
models. Prognostic associations were determined if there was a
significant (p  0.05) characteristic main effect within the
regression models. Pairwise comparisons were performed using
Cox-adjusted analysis.
RESULTS
A total of 612 patients entered the study between
August 1998 and May 2000 and were randomized; 607 were
treated (205 GC, 201 PCb, and 201 VC). Baseline character-
istics were well balanced among treatment arms (Table 1).
When the baseline characteristics were examined by histol-
ogy, independent of treatment received, each characteristic
varied slightly with the exception of disease stage. For ex-
ample, patients with squamous cell carcinoma were more
likely (approximately 10%) to be male, have PS of 0/1, not to
have multiple metastatic sites, and have a history of smoking
(data not shown). Analyses of efficacy endpoints (adjusted
and unadjusted) showed no significant differences between
treatment arms.9
Using Cox multiple regression analysis of OS and TTP,
the potential predictive and prognostic role of histology was
examined using two histology models (Table 2). No signifi-
cant treatment-by-histology interaction was seen in either
model for either end point (Table 2, column 4, all values p 
0.10), confirming that histology was not predictive of efficacy
outcomes for any of the three regimens. Considering the
treatment effect (Table 2, column 2), neither model showed
any significant differences between treatments. In model 1,
histology was a significant prognostic factor for OS (p 
0.0183) and was marginally significant for TTP (p  0.0783)
(Table 2, column 3). Nevertheless, model 2 did not identify
histology as a prognostic factor. Additional Cox regression
analyses identified gender, PS, number of metastatic sites,
and smoking history as significant prognostic factors for OS
(p  0.05) in both models; the same factors, except gender,
were also significant for TTP (p  0.05).
After histology was identified as a significant prognos-
tic factor using model 1 (p 0.018), pairwise comparisons of
histologic groups for survival were performed (Table 3). The
comparisons revealed a statistically significant survival ad-
TABLE 1. Baseline Patient and Disease Characteristics
Characteristics
Percentage of Patients
GC
(N  205)
PCb
(N  201)
VC
(N  201)
Male 81 76 78
ECOG performance
status 0 or 1
95 92 92
Stage IV disease 81 82 81
Histology
Adenocarcinoma 50 48 55
Squamous cell
carcinoma
33 32 27
Large cell carcinoma 6 10 6
NSCLC not otherwise
specified (NOS)/other
11 10 11
1 Metastatic sitea 26 28 33
Smoking history 80 77 82
a N  167 for GC, 164 for PCb, and 163 for VC.
ECOG, Eastern Cooperative Oncology Group; GC, gemcitabine/cisplatin; NSCLC,
non-small cell lung cancer; PCb, paclitaxel/carboplatin; VC, vinorelbine/cisplatin.
TABLE 2. Cox Regression Results (p)a
Treatment Histology
Treatment-by-
Histology
Interaction
Model 1 (four histologic
groupsb)
Survival 0.6302 0.0183 0.2326
TTP 0.2629 0.0783 0.3397
Model 2 (nonsquamous vs.
squamous)
Survival 0.6089 0.1005 0.5235
TTP 0.2590 0.7196 0.1674
a Bold p is significant.
b The four histologic groups in model 1 were squamous cell carcinoma, adenocar-
cinoma, large cell carcinoma, or other.
Nonsquamous, all non-small cell lung cancer histologic types except squamous cell
carcinoma; squamous, squamous cell carcinoma; TTP, time to progression.
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vantage for squamous cell carcinoma over adenocarcinoma
(p  0.0021). To a lesser extent, “other” histology was
associated with longer survival than adenocarcinoma. Other
pairwise comparisons were not significant. Survival by his-
tology was plotted for the combined treatment arms to illus-
trate these findings (Figure 1).
DISCUSSION
This retrospective analysis of the phase III trial9 did not
identify any significant difference in the efficacy of three
cytotoxic chemotherapy regimens according to histology.
Among common cytotoxic therapies for advanced NSCLC,
histology may only be a predictive factor of efficacy for
pemetrexed-containing regimens. Although a mechanistic un-
derstanding of this phenomenon is not entirely clear, the
differential expression of thymidylate synthase in adenocar-
cinoma and squamous cell carcinoma11 might contribute to
the differential efficacy of pemetrexed by histology. As an
agent that inhibits thymidylate synthase and other enzymes
involved in purine and pyrimidine synthesis,12 pemetrexed
would be less efficacious when these targeted, folate-depen-
dent enzymes are highly expressed,13 as they are in squamous
cell carcinoma.
This analysis also investigated a potential prognostic
role for histology in advanced NSCLC. Histology was found
to be prognostic for survival, with better outcomes associated
with squamous cell carcinoma and poorer outcomes with
adenocarcinoma. Although previous studies have also sug-
gested a prognostic role for histology, this has not been
consistently reported.3 As summarized by other authors,3
among studies which tested chemotherapy in advanced
NSCLC and identified a possible prognostic role for histol-
ogy, approximately half concluded that squamous cell carci-
noma (or nonadenocarcinoma) was associated with better
outcomes, and half concluded that adenocarcinoma or
nonsquamous histology was associated with better out-
comes.3 These different outcomes may well have to do with
differences in subsequent lines of therapy, including the use
of epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitors that have been shown to improve the survival of
patients with EGFR mutations, which are usually seen in
patients with adenocarcinoma.14 Nevertheless, EGFR-inhibi-
tors would not have impacted the study results presented here
as they were not in general use during the years these data
were collected (1998–2000).
In this analysis, histology was identified as a prognostic
factor only when analyzed as four separate groups (model 1)
but not when analyzed as two groups (model 2). This under-
scores the need to use multiple models when investigating
these associations. Differential outcomes were confined to the
two most distinct histologic groups, with squamous cell
carcinoma performing significantly better than adenocarci-
noma. When adenocarcinoma was analyzed in combination
with large cell carcinoma and other histologic groups (col-
lectively referred to as nonsquamous), the separation of
adenocarcinoma and squamous was less pronounced. Al-
though combining histologic groups is often necessary and
appropriate, initial analysis using separate histologic groups
may yield additional insight.
Interpretation of the presented results must acknowl-
edge the limitations of this analysis, including the limited
sample size, especially in the large cell and “other” histologic
groups; a study population derived from a single country (all
Italian study sites); and data derived from a study that
FIGURE 1. Kaplan-Meier plot of overall survival by histol-
ogy for combined treatment arms.
TABLE 3. Pairwise Comparisons of NSCLC Histologic Groups for Survival: Hazard Ratiosa
and pb
Squamous
(n  187)
Adenocarcinoma
(n  310)
Large cell
(n  54)
Other
(n  65)
Squamous — 0.0021 0.1607 0.9724
Adenocarcinoma 1.42 (1.14–1.78) — 0.6953 0.0239
Large cell 1.32 (0.89–1.96) 0.93 (0.64–1.34) — 0.2090
Other 0.99 (0.71–1.39) 0.70 (0.51–0.95) 0.75 (0.48–1.17) —
a Hazard ratios with 95% confidence intervals (in parentheses) are provided in the lower left data grouping. Reference histologic group in
column heading; hazard ratios 1 indicate lower risk of death in histologic group in the column heading.
b Comparison p are provided in the upper right data grouping. Bold p are significant.
Large cell, large cell carcinoma; NSCLC, non-small cell lung cancer; squamous, squamous cell carcinoma.
Scagliotti et al. Journal of Thoracic Oncology • Volume 4, Number 12, December 2009
Copyright © 2009 by the International Association for the Study of Lung Cancer1570
enrolled patients a decade ago. Regarding the latter point,
evidence suggests that advanced NSCLC presentation and
responsiveness have been affected over time by multiple
factors. For example, changes in cigarette composition and
design over the last few decades are thought to have influ-
enced NSCLC histologic distribution.15 Additionally, the def-
initions of NSCLC histologic categories have been refined in
the last several years, potentially altering the composition of
some categories of NSCLC histologic types.3
In conclusion, this retrospective analysis identified a
prognostic role for histology in advanced NSCLC, with better
outcomes associated with squamous cell carcinoma; how-
ever, histology did not predict differential efficacy for PCb,
GC, or VC. Evidence presented here and in other recent
reports5–8 suggests that studies should continue to investigate
histology and its possible association with efficacy outcomes
in patients with advanced NSCLC.
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